{
  "issued_date": "2014-01-08", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON362331", 
  "doc_details": {
    "Type": "Drug Alert", 
    "Series No": "EL (14)A/01", 
    "Audience": "Healthcare professional", 
    "Published": "8 January 2014", 
    "Format": "Electronic", 
    "Size": "A4", 
    "Pages": "1", 
    "Price": "Free", 
    "ISBN/ISSN": "", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": " Class 4 Medicines Recall (Caution in Use): Irbesartan / Hydrochorothiazide Teva 300/12.5mg and 300/25mg film-coated tablets -  Teva UK Ltd (EL (14)A/01) (68Kb)", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/is-md/documents/drugalert/con362332.pdf", 
      "filename": "downloads/cc91fc7bd367a788dfd004492eee0ee3dc5a01a2/con362332.pdf", 
      "original_filename": "con362332.pdf"
    }
  ], 
  "body": "## DRUG ALERT\n\nCLASS 4 MEDICINES DEFECT INFORMATION\n\nCaution in use\n\n  \n\n\nDistribute to pharmacy and dispensing clinic level  \n  \n08 January 2014  |   |  EL (14)A/01  |   |  Our ref:\u00a0 MDR 64-12/13   | \n\n* * *\n\nDear Healthcare Professional,\n\nTeva Pharma B.V. (Trading as Teva UK Ltd)\n\nIrbesartan / Hydrochorothiazide Teva 300/12.5mg film-coated tablets\n\nIrbesartan / Hydrochorothiazide Teva 300/25mg film-coated tablets\n\nEU/1/09/583/0077 and EU/1/09/583/0078\n\nTeva UK Ltd has informed MHRA that an incorrect dosing instruction is present in the Patient Information Leaflet for Irbesartan / Hydrochorothiazide, Teva strength combinations 300/12.5 mg & 300/25 mg.\n\nThe recommended dose of Irbesartan / Hydrochlorothiazide Teva is one tablet a day.\n\nThe Patient Information Leaflet incorrectly states one or two tablets a day.\u00a0 If taken according to the wrong recommendation in the Patient Information Leaflet, patients are at risk of overdose.\u00a0 No cases of overdose with the combination of irbesartan with hydrochlorothiazide have been reported to date.\n\nIrbesartan / Hydrochorothiazide Teva is prescribed by a healthcare professional and patients following the prescribing advice provided are not at risk.\n\nFor further information, please telephone Teva UK Ltd medical information on 020 7540 7117 or by email to [medinfo@tevauk.com](mailto:%20medinfo@tevauk.com).\n\nDistribution of affected stock has ceased and this issue is being corrected by the manufacturer, however to avoid an impact to supply affected product will remain in the market for a short period of time.\n\nRecipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.\n\nYours faithfully\n\nAdam Burgess  \nDefective Medicines Report Centre  \n151 Buckingham Palace Road  \nLondon  \nSW1W 9SZ  \nTelephone +44 (0)20 3080 6574\n\nMHRA Distribution (further recipients by cascade):  N/A \n\n### Download documents:  \n  \n  * [ASSET_TAG](#ASSET0)\n", 
  "raw_html": "<div class=\"inner\">          \r\n\t\t\t\t<a name=\"main\"></a>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"title\">\r\n\t\t\t\t\t<h2>DRUG ALERT</h2>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element14)-->\r\n\t\t\t\t\t<p>CLASS 4 MEDICINES DEFECT INFORMATION</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element14)-->\r\n\t\t\t\t</div>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"drugalertdetails\">\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<p>Caution in use</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<br>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element16)-->\r\n\t\t\t\t\t<p>Distribute to pharmacy and dispensing clinic level</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element16)-->\r\n\t\t\t\r\n\t\t\t\t\t<table id=\"dateref\">\r\n\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t<td align=\"left\">\r\n\t\t\t\t\t\t\t\r\n\r\n\t\t\t\t\t\t\t08 January 2014\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td>\r\n\t\t\t\t\t\t\tEL (14)A/01\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td align=\"right\">\r\n\t\t\t\t\t\t\t\tOur ref:&#160;\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t\t MDR 64-12/13 \r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t</table>\r\n\t\t\t\t</div>\r\n\t\t\t\t<hr>\t\t\t\t\r\n          \t\t<!--SS_BEGIN_ELEMENT(region1_element12)-->\r\n          \t\t<!--SS_END_ELEMENT(region1_element12)--> \r\n          \t\t\r\n          \t\t \r\n          \t\t\r\n          \t\t<p>Dear Healthcare Professional,</p>\r\n\r\n\t\t\t\t<div class=\"druginfo\">\r\n\t\t\t\t\t<div class=\"left\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Teva Pharma B.V. (Trading as Teva UK Ltd)</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\t\t\t\t\r\n          \t\t          \t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Irbesartan / Hydrochorothiazide Teva 300/12.5mg film-coated tablets</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Irbesartan / Hydrochorothiazide Teva 300/25mg film-coated tablets</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\r\n\t\t\t\t\t\r\n\t\t\t\t\t<div class=\"right\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<span>EU/1/09/583/0077 and EU/1/09/583/0078</span>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\t\r\n\t\t\t\t</div>\t\t\t\t\r\n          \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment8,navigation_controls)-->\r\n\t\t\t\t<!-- only show the publication navigation controls if there is more than one page to the publication -->\r\n\t\t\t\r\n\t\t\t\t<!-- SS_END_SNIPPET(fragment8,navigation_controls)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t<!-- <br>SS_DATAFILE: CON362331 -->\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<p></p><p>Teva UK Ltd has informed MHRA that an incorrect dosing instruction is present in the Patient Information Leaflet for Irbesartan / Hydrochorothiazide, Teva strength combinations 300/12.5 mg &amp; 300/25 mg.</p>\n\n<p>The recommended dose of Irbesartan / Hydrochlorothiazide Teva is one tablet a day.</p>\n\n<p>The Patient Information Leaflet incorrectly states one or two tablets a day.&#160; If taken according to the wrong recommendation in the Patient Information Leaflet, patients are at risk of overdose.&#160; No cases of overdose with the combination of irbesartan with hydrochlorothiazide have been reported to date.</p>\n\n<p>Irbesartan / Hydrochorothiazide Teva is prescribed by a healthcare professional and patients following the prescribing advice provided are not at risk.</p>\n\n<p>For further information, please telephone Teva UK Ltd medical information on 020 7540 7117 or by email to <a href=\"mailto:%20medinfo@tevauk.com\">medinfo@tevauk.com</a>.</p>\n\n<p>Distribution of affected stock has ceased and this issue is being corrected by the manufacturer, however to avoid an impact to supply affected product will remain in the market for a short period of time.</p>\n\n<p>Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.</p>\n\n<p>Yours faithfully</p>\n\n<p>Adam Burgess<br>\n<span>Defective Medicines Report Centre<br>\n151 Buckingham Palace Road<br>\nLondon<br>\nSW1W 9SZ<br>\nTelephone +44 (0)20 3080 6574</span></p>\r\n\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t\r\n        \t\tMHRA Distribution (further recipients by cascade):\r\n        \t\t\r\n        \t\t <!--SS_BEGIN_ELEMENT(region1_element18)-->\r\n        \t\tN/A\r\n        \t\t<!--SS_END_ELEMENT(region1_element18)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element3,static_pdf_list)-->\r\n        \t\t<!-- the xmlListTag variable is used by the searchDocsByContentIdList include to map the name of the XML node which contains the content id -->\r\n<!--perform the search -->\r\n\t\r\n\t<!-- <br>root: Content/AssociatedContent -->\r\n\t<!-- <br>ssFragmentInstanceId: region1_element3\t -->\r\n\t<!-- <br>SS_DATAFILE: CON362331 -->\r\n\t<!-- <br>xmlListTag: ContentId\t -->\r\n\t<!-- <br>XPATH: CON362331/Content/AssociatedContent/ContentId\t -->\r\n\r\n\t<!-- xmlListTag variable should be the name of the xml node which contains a contentid.  there should be a lis of these in the XML -->\r\n\t<!-- <br>strNumRecords: 1 -->\r\n\t<!-- <br>nNumRecords: 1 -->\r\n\r\n\t\t\t<!-- using the content ID above, get the docment from conetent server-->\r\n\r\n\t\t\t\r\n\r\n\t\t<!--  dDocName <matches>`CON362332` -->\r\n\t\t\r\n<div id=\"downloadArea\">\r\n\t<h3>Download documents:</h3>\r\n\t<ul>\r\n\t\t<!-- the SearchResults will have been initialised by the call to searchDocsByContentIdList above-->\r\n\t\t\t\r\n\t\t\t\t<li>\r\n\r\n\t\t\t\t\t\t<a href=\"#ASSET0\">ASSET_TAG</a>\r\n\t\t\t\t</li>\r\n\t</ul>\r\n\t<div class=\"clearing\"><!--  --></div>\r\n\t<!--<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/readstep2.html\">Download Acrobat Reader for free</a></p>\r\n\t<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/access_onlinetools.html\">Adobe text conversion tools</a></p>-->\r\n</div>\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element3,static_pdf_list)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_CLOSEREGIONMARKER(region1)-->\r\n        \t\t\r\n        \t\t<!-- SS_END_CLOSEREGIONMARKER(region1)-->\r\n\t\t\t</div>\r\n\t\t", 
  "title": "Class 4 Medicines Recall (Caution in Use): Irbesartan / Hydrochorothiazide Teva 300/12.5mg and 300/25mg film-coated tablets -  Teva UK Ltd (EL (14)A/01)", 
  "alert_type": [
    "drugs"
  ], 
  "medical_specialism": []
}